←Back to list

Resilience

Biomanufacturing CDMO improving access to complex medicines
Biotech 📍 Blue Ash, OH Founded 2020
Current Valuation
$9.4B
as of 2023-Q1
UNICORN

IPO Outlookprivate

Is Resilience going public?
No. Resilience has no imminent IPO plans on record. It is still private.
What is Resilience's valuation in 2026?
Resilience is valued at $9.4B as of 2023-Q1, set by its Series D ($625M, Jan 2023). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Resilience filed an S-1?
No public S-1 is on file for Resilience.
Who are Resilience's investors?
Resilience's investors include GIC, ARCH Venture Partners, 8VC, Andreessen Horowitz, NEA.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Resilience (legal name National Resilience) is a biomanufacturing contract development and manufacturing organization (CDMO) building end-to-end manufacturing capacity for biologics, cell & gene therapies, and other complex medicines. Founded in 2020 and last priced at $9.4B in early 2023, it operates a network of US and Canadian manufacturing facilities.

Company Profile

CEO
Rahul Singhvi
Founded
2020
HQ
Blue Ash, OH
Employees
~2500
Total Raised
$2.1B
Growth
Raised more than $2B since its 2020 founding to build a domestic biomanufacturing network, then reset: it is winding down six manufacturing sites, has cut staff including 120 in North Carolina, and took a $250M bridge to continue as a streamlined CDMO. The $9.4B Series D mark from January 2023 predates all of that.
Last Round
Series D — $625M (Jan 2023) · Lead: GIC
IPO Status
no imminent plans

Fundraising Status

Series D · $625M · 3y 7mo ago
no imminent plansTotal raised $2.1B

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series D$625MJan 2023GIC—

Vertical Intelligence — Biotech / Gene Therapy

Registered trials
3
3 active · 2 recruiting
Lead phase
Phase 3
most advanced registered study
Focus areas
Mood Disorder (Depressive Episodes)
IBD · Cancer
Latest trial start
2025-10-31
Name-verified against lead sponsor "Resilience" on ClinicalTrials.gov as of 2026-08-19. Verify on ClinicalTrials.gov ↗

Talent Signal

Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
73
via workday
Product-build share
63%
engineering, research, product, design
Trajectory
steady
product-led hiring — 63% of open roles build product; the rest are go-to-market and G&A.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by month73Aug '26
Open roles by function
Open roles by functionHardware28Other20Engineering17Ops & People6Research1Finance & Strategy1
■ product-building   ■ go-to-market / G&A
Manufacturing Technician IIProcess Engineer III - Sterile Operations (Night Shift))Supervisor, Manufacturing - DAP (Night shift)Manufacturing Technician IIManufacturing Technician II - Sterile FillingManufacturing Technician IV, Lead - DAP (Night Shift)
Counted from Resilience's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.

Founders & Key People

Rahul SinghviRobert Nelsen

Investors

GIC · ARCH Venture Partners · 8VC · Andreessen Horowitz · NEA

Products

  • Biologics manufacturing
  • Cell & gene therapy CDMO
  • Drug substance & drug product
  • Fill-finish

Competitors

Lonza · Catalent · Samsung Biologics · WuXi Biologics
BiotechBiomanufacturingCDMODecacorn
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2023-Q1. Refreshed quarterly.